title: Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
abstract: OBJECTIVE
  Methotrexate (MTX) in low doses is used in the therapy of rheumatoid arthritis (RA). The aim of many studies is to identify factors predicting the outcome of treatment with methotrexate in rheumatoid arthritis. The action of MTX in RA is associated with the inhibition of inflammatory mediators synthesis. CXCL9 and CXCL10 chemokines play the important role in inflammatory response in RA patients. The aim of this study was to examine the association between CXCL9/10 gene polymorphisms and response to therapy of RA patients with MTX.
  
  
  METHODS
  The study included 422 patients diagnosed with rheumatoid arthritis, treated with MTX in doses 20 mg weekly. Good responders were defined as patients who were receiving MTX and had a DAS28 of ≤ 2.5 at 6 months of therapy. Poor-responders were defined as patients who were receiving MTX and had a DAS28 of > 2.5.
  
  
  RESULTS
  There were not statistically significant associations between studied polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
  
  
  CONCLUSIONS
  The results of this study suggest lack of associations between the polymorphisms in CXCL9 and CXCL10 genes and the response to MTX in RA patients.
authors.affiliation: Departament of Orthopaedics, Traumatology and Orthopaedic Oncology, Pomeranian Medical University, Szczecin, Poland. pawand@poczta.onet.pl.
authors.forename: D
authors.initials: D
authors.lastname: Kotrych
authors.forename: V
authors.initials: V
authors.lastname: Dziedziejko
authors.forename: K
authors.initials: K
authors.lastname: Safranow
authors.forename: A
authors.initials: A
authors.lastname: Pawlik
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D054357:Chemokine CXCL10 / Q000235:genetics*; D054370:Chemokine CXCL9 / Q000235:genetics*; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; C114753:CXCL10 protein, human; C080810:CXCL9 protein, human; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D008727:Methotrexate